Treating Lower Extremity Ischemia with JETi Clinical Data | Abbott
CARDIOVASCULAR
hamburger
BACK
JETi™ Hydrodynamic Thrombectomy System
Single-center experience for acute and subacute lower extremity ischemia

Request a hands-on demonstration

Percutaneous mechanical thrombectomy treatment of patients with acute and subacute lower extremity ischemia

Overview: Retrospective Study1

Dandu et al., VAM. 2022.

Background
Acute lower extremity ischemia (ALEI) is a vascular emergency with a mortality rate of 15-20%2. Treatment is multifaceted and is typically aimed at restoring blood flow and can be performed surgically, endovascularly, or through a hybrid method.3

Methods
Single-center retrospective review of 27 ALEI patients treated with the JETi™ System. 89% of patients met criteria for Rutherford IIa or IIb classification. Patients were treated endovascularly or through a hybrid surgical approach. Adjunctive treatment included angioplasty, stenting and open thrombectomy.

Endpoints
Removal of over 50% of clot burden from target artery, restoration of inline flow. Indications, limb salvage, and major adverse events were reviewed.

Clinical Outcomes1

Despite a challenging patient population, target thrombus was successfully removed in 85% of JETi™ cases with zero patient deaths at 30 days.

Target Thrombus Successfully Removed JETi™
JETi™ Alone 26%
(7/27)
JETi™ + Adjunctive Procedures* 59%
(16/27)
Overall (Includes JETi™ Alone and JETi™ + Adjunctive Procedures) 85%
(23/27)

*Angioplasty, stenting, open thrombectomy.

JETi™, alone or with adjunctive procedures, was successful in removing target thrombus in 85% of cases.

JETi Remove Target Thrombus in ALEI Patients

Zero deaths and only four major limb amputations were reported at 30-days in this challenging population.

Clinical Data Demonstrating Zero Deaths with JETi

JETi™ is a safe and efficacious tool for the treatment of acute lower extremity ischemia (ALEI).

JETi Safety Data for ALEI

References:

  1. Dandu et al., VAM 2022.
  2. Baril et al. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. J Vasc Surg. 2014;60(3):669-77.e2.
  3. Olinic et al. Acute Limb Ischemia: An Update on Diagnosis and Management. J Clin Med. 2019;8(8):1215. Published 2019 Aug 14.
Important Safety Information
Request a Demo

MAT-2207738 v1.0

IMPORTANT SAFETY INFORMATION

rx-only-logo  JETi™ All-In-One Peripheral Thrombectomy System


Indications

The JETi™ AIO Peripheral Thrombectomy System is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to sub selectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion.
 

Contraindications

The JETi™ AIO Peripheral Thrombectomy System is contraindicated for use in:

  • Vessels smaller than 4 mm (0.16”)
  • Coronary, pulmonary, and neurovasculature


Warnings

The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, and JETi™ Pump Set contents are supplied sterile using EO. Do not use if the expiration date has passed or the sterile barrier is damaged.

  • The JETi™ Peripheral Catheter, JETi™ AIO Suction Tubing, JETi™ AIO Non-Sterile Kit, and JETi™ Pump Set contents are for single patient use only. Dispose after use. Do not reuse, reprocess, modify, or resterilize. Reuse, reprocessing, modification, or resterilization may compromise the structural integrity of the device and/or lead to device failure which, may result in patient injury, illness or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness, or death of the patient.
  • The JETi™ AIO Peripheral Thrombectomy System is not approved for use with defibrillation. In the event shock must be delivered to the patient, remove the catheter and clear all connected system components from the patient before delivering shock.
  • Do not use a catheter that has been kinked or damaged.
  • Do not use a pump set if it does not prime.
  • Only use the JETi™ Peripheral Catheter and JETi™ AIO Suction Tubing with the JETi™ AIO Peripheral SDU.
  • Do not mix contrast media in the saline bag.
  • When the catheter is exposed to the arterial system, it should be manipulated while under high-quality fluoroscopic observation.
  • In the event that the catheter becomes blocked or clogged with thrombus, remove and replace the device with a new device.
  • Do not use if package is opened or damaged.
  • To avoid risk of electric shock, the SDU must only be connected to mains power with a protective earth.
  • The power socket-outlet must be located near the device and must be easily accessible.
  • Do not modify or alter the device.
  • Do not step or stand on the base of the device.
  • Do not push or lean against the IV pole.


Precautions

Physicians must read and understand the Instructions for Use (IFU) prior to using the device. The device must be used by physicians skilled in percutaneous, intravascular techniques in a fully equipped catheterization laboratory.
 

Potential Adverse Effects

Potential adverse events include, but are not limited to:

  • Acute closure
  • Aneurysm or pseudo aneurysm
  • Allergic reaction to contrast
  • Arrhythmia
  • Death
  • Embolism (air or device)
  • Embolization (thrombotic)
  • Emergency surgery
  • Access site pain, hemorrhage, or hematoma
  • Infection (systemic/sepsis)
  • Local infection (puncture site)
  • Minimal blood loss
  • Vessel dissection, perforation, or other injury
  • Vessel spasm
  • Thrombosis

JETi™ is a trademark of Walk Vascular. Walk Vascular is a subsidiary of the Abbott Group of Companies.
Manufactured by Walk Vascular LLC 17171 Daimler Street, Irvine CA, 92614 USA

MAT-2116195 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

Precautions


Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.



Are you a healthcare professional?

 

Test

yesno